AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9531003 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum intake of carbohydrate-electrolyte solution
Number of subjects: 7
Study 9531003 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed intake of carbohydrate-electrolyte solution
Number of subjects: 7
Study 8270977 — intervention group
Group type: EXPERIMENTAL
Intervention: L-PAM plus BSO
Number of subjects: 28
Study 8270977 — intervention group
Group type: COMPARATOR
Intervention: L-PAM alone
Number of subjects: 28
Study 8270977 — intervention group
Group type: EXPERIMENTAL
Intervention: BSO
Number of subjects: 28
Study 2481741 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclobenzaprine (Flexeril)
Number of subjects: 40
Study 2481741 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 53377 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 5
Study 53377 — intervention group
Group type: COMPARATOR
Intervention: Frusemide
Number of subjects: 5
Study 31288820 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide (1.8 mg/day)
Number of subjects: 47
Study 31288820 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 47
Study 28339462 — intervention group
Group type: EXPERIMENTAL
Intervention: Picaridin repellent
Number of subjects: 25000
Study 25492378 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 40
Study 25492378 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented therapy
Number of subjects: 40
Study 23453824 — intervention group
Group type: COMPARATOR
Intervention: Cold exposure (4°C) during recovery
Number of subjects: 20
Study 23453824 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperate conditions (24°C) during recovery
Number of subjects: 20
Study 21255828 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B (1 mg/kg infusion on alternate days for 30 days, total dose 15 mg/kg)
Number of subjects: 634
Study 21255828 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B with miltefosine (single injection of 5 mg/kg liposomal amphotericin B and 7-day 50 mg oral miltefosine)
Number of subjects: 634
Study 21255828 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B with paromomycin (single 10-day 11 mg/kg intramuscular paromomycin)
Number of subjects: 634
Study 21255828 — intervention group
Group type: EXPERIMENTAL
Intervention: Miltefosine and paromomycin (10 days each of miltefosine and paromomycin)
Number of subjects: 634
Study 19229978 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic compression guided by mean artery pressure (MAP) after the procedure (Group A)
Number of subjects: 351
Study 19229978 — intervention group
Group type: COMPARATOR
Intervention: Standard pneumatic compression (15 cm³ of air in the device) (Group B)
Number of subjects: 351
Study 16517515 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint‐Induced Movement Therapy (CIMT)
Number of subjects: 8
Study 16517515 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy (Control)
Number of subjects: 8
Study 16517515 — intervention group
Group type: EXPERIMENTAL
Intervention: CIMT
Number of subjects: 8
Study 12939591 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b plus ribavirin (PEG/R)
Number of subjects: 0
Study 12939591 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 10681486 — intervention group
Group type: EXPERIMENTAL
Intervention: triflusal 600 mg once daily for 35 days
Number of subjects: 2124
Study 10681486 — intervention group
Group type: COMPARATOR
Intervention: aspirin 300 mg once daily for 35 days
Number of subjects: 2124
Study 9018764 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide oxide (4 mg twice daily for 1 week)
Number of subjects: 11
Study 9018764 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide oxide
Number of subjects: 11
Study 9018764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7940002 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoplasty
Number of subjects: 50
Study 7940002 — intervention group
Group type: COMPARATOR
Intervention: Fusion without thoracoplasty (Control)
Number of subjects: 50
Study 3124721 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training program
Number of subjects: 0
Study 3124721 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30472404 — intervention group
Group type: EXPERIMENTAL
Intervention: WT combining with PSBL
Number of subjects: 20
Study 30472404 — intervention group
Group type: COMPARATOR
Intervention: Conventional training (CT)
Number of subjects: 20
Study 29482543 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment (NSPT) with immediate ultrasonic scaling, scaling and root planning, and subgingival 10% povidone iodine irrigation.
Number of subjects: 34
Study 29482543 — intervention group
Group type: COMPARATOR
Intervention: Education only (control group).
Number of subjects: 34
Study 28471557 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D Quantitative Coronary Angiography (3D-QCA)
Number of subjects: 17
Study 28471557 — intervention group
Group type: COMPARATOR
Intervention: 2D Quantitative Coronary Angiography (2D-QCA)
Number of subjects: 17
Study 28471557 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable Vascular Scaffold (BVS)
Number of subjects: 17
Study 25446768 — intervention group
Group type: EXPERIMENTAL
Intervention: Thickened amino-acid formula (TAAF)
Number of subjects: 86
Study 25446768 — intervention group
Group type: COMPARATOR
Intervention: Reference amino-acid formula (RAAF)
Number of subjects: 86
Study 22686269 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk Reduction through Family Therapy (RRFT)
Number of subjects: 30
Study 22686269 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 30
Study 20046552 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual treatment technique (4-minute pain-alleviating traction) at the most symptomatic zygopophyseal joint
Number of subjects: 126
Study 20046552 — intervention group
Group type: COMPARATOR
Intervention: Manual treatment technique (4-minute pain-alleviating traction) 3 segments away from the concordant segment
Number of subjects: 126
Study 17895349 — intervention group
Group type: EXPERIMENTAL
Intervention: BWSTT/UE‐EX
Number of subjects: 80
Study 17895349 — intervention group
Group type: COMPARATOR
Intervention: CYCLE/UE‐EX
Number of subjects: 80
Study 17895349 — intervention group
Group type: EXPERIMENTAL
Intervention: BWSTT groups (BWSTT/LE‐EX, BWSTT/CYCLE, BWSTT/UE‐EX)
Number of subjects: 80
Study 15102867 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg bid IV for 6 days with UFH on day 5 (n = 18)
Number of subjects: 36
Study 15102867 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) alone (n = 18)
Number of subjects: 36
Study 12122123 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment for Charcot's arthropathy; specific intervention details not provided.
Number of subjects: 0
Study 9457187 — intervention group
Group type: EXPERIMENTAL
Intervention: SH U 555 A (4 mumol Fe/kg)
Number of subjects: 169
Study 9457187 — intervention group
Group type: EXPERIMENTAL
Intervention: SH U 555 A (16 mumol Fe/kg)
Number of subjects: 169
Study 9457187 — intervention group
Group type: EXPERIMENTAL
Intervention: SH U 555 A (8 mumol Fe/kg)
Number of subjects: 169
Study 7783654 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasodilator administration (prazosin and hydralazine) alone or in combination with a beta‐blocker (propranolol)
Number of subjects: 13
Study 7783654 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 13
Study 7783654 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (vasodilators + propranolol)
Number of subjects: 13
Study 2295294 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (CCK antagonist), 800 mg (two tablets of 400 mg each)
Number of subjects: 10
Study 2295294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 381006 — intervention group
Group type: EXPERIMENTAL
Intervention: (‐)eburnamonine (80 mg/day for the first 5 days, then 60 mg/day for at least 20 days)
Number of subjects: 28
Study 381006 — intervention group
Group type: COMPARATOR
Intervention: Nicergoline (20 mg/day for the first 5 days, then 15 mg/day for at least 20 days)
Number of subjects: 28
Study 7013976 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (300 mg/kg)
Number of subjects: 51
Study 7013976 — intervention group
Group type: COMPARATOR
Intervention: Cycloleucine (300 mg/kg)
Number of subjects: 51
Study 7013976 — intervention group
Group type: COMPARATOR
Intervention: Cycloleucine (200 mg/kg)
Number of subjects: 51
Study 30834253 — intervention group
Group type: EXPERIMENTAL
Intervention: Galphimine-B standardized extract
Number of subjects: 167
Study 30834253 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam (control)
Number of subjects: 167
Study 28762160 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy for children with ASD
Number of subjects: 57
Study 28762160 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted parents (Control)
Number of subjects: 57
Study 28762160 — intervention group
Group type: EXPERIMENTAL
Intervention: All parents (including treatment and control)
Number of subjects: 57
Study 26106962 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination formulation
Number of subjects: 161
Study 26106962 — intervention group
Group type: COMPARATOR
Intervention: Separate formulations
Number of subjects: 161
Study 26106962 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 161
Study 24400967 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding self-efficacy intervention (three individualized sessions)
Number of subjects: 74
Study 24400967 — intervention group
Group type: COMPARATOR
Intervention: Standard care (referent group)
Number of subjects: 74
Study 22695489 — intervention group
Group type: EXPERIMENTAL
Intervention: Almorexant 400 mg
Number of subjects: 40
Study 22695489 — intervention group
Group type: EXPERIMENTAL
Intervention: Almorexant 1000 mg
Number of subjects: 40
Study 22695489 — intervention group
Group type: EXPERIMENTAL
Intervention: Almorexant (evening administration)
Number of subjects: 40
Study 22695489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19947279 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 978
Study 19947279 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 978
Study 17526469 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10-20 mg/d) with diet modifications (500 kcal/d less than usual) and moderate physical activity (jogging lightly for 30 min 3 times a week)
Number of subjects: 28
Study 17526469 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (10-20 mg/d) only
Number of subjects: 28
Study 15583924 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) with HELBO Blue and TheraLite laser
Number of subjects: 100
Study 15583924 — intervention group
Group type: COMPARATOR
Intervention: Control group without aPDT
Number of subjects: 100
Study 15583924 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT)
Number of subjects: 100
Study 12297170 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (2 x 10(6) KIU loading dose and 0.5 x 10(6) KIU/h during surgery, n=22)
Number of subjects: 47
Study 12297170 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control, n=25)
Number of subjects: 47
Study 12297170 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (n=22)
Number of subjects: 47
Study 10429750 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (received the intervention in spring 1994)
Number of subjects: 27
Study 10429750 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (received the intervention in spring 1995)
Number of subjects: 27
Study 10429750 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (parents of children attending centers in the intervention group)
Number of subjects: 27
Study 7770327 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource allocation manipulation through dual task priority
Number of subjects: 0
Study 7770327 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal predictability manipulation of discrete stimuli
Number of subjects: 0
Study 2179711 — intervention group
Group type: EXPERIMENTAL
Intervention: Gen-Probe (chemiluminescent technique of nucleic acid hybridization)
Number of subjects: 187
Study 2179711 — intervention group
Group type: COMPARATOR
Intervention: Chlamydiazyme (Abbott Labs)
Number of subjects: 187
Study 2179711 — intervention group
Group type: COMPARATOR
Intervention: MicroTrak (Syva)
Number of subjects: 187
Study 383287 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methanol extraction residue fraction of Bacillus Calmette-Guérin (MER) (2.0 mg)
Number of subjects: 84
Study 383287 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methanol extraction residue fraction of Bacillus Calmette-Guérin (MER) (0.5 mg)
Number of subjects: 84
Study 383287 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl solution placebo
Number of subjects: 84
Study 31304775 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) at 2 mA for 20 minutes per session, with 30 seconds ramp-up and ramp-down.
Number of subjects: 30
Study 31304775 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (30 seconds ramp-up to 2 mA, 10 seconds stimulation, 30 seconds ramp-down, and 20 minutes no current).
Number of subjects: 30
Study 28526870 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular strength endurance (SE)
Number of subjects: 45
Study 28526870 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular hypertrophy (MH)
Number of subjects: 45
Study 28526870 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum strength (MS)
Number of subjects: 45
Study 26200180 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic normoglycemic clamp (HNC)
Number of subjects: 100
Study 26200180 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (insulin treatment if glucose >150 mg/dl)
Number of subjects: 100
Study 23455443 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 353
Study 23455443 — intervention group
Group type: COMPARATOR
Intervention: Enteral Nutrition (EN+PN)
Number of subjects: 353
Study 21801540 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostatin (lipid-lowering drug)
Number of subjects: 900
Study 19855033 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI, higher age, and higher numbers of current somatic and mental disorders
Number of subjects: 640
Study 19855033 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher numbers of both mental and somatic disorders, female gender, and younger age
Number of subjects: 640
Study 19855033 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 640
Study 19855033 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy status
Number of subjects: 640
Study 17112001 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan plus cisplatin (TC)
Number of subjects: 293
Study 17112001 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin monotherapy
Number of subjects: 293
Study 15293627 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic factor
Number of subjects: 0
Study 15293627 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox model
Number of subjects: 0
Study 12110777 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate supplementation
Number of subjects: 50
Study 12110777 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 50
Study 9449397 — intervention group
Group type: EXPERIMENTAL
Intervention: Ang I infusion
Number of subjects: 17
Study 9449397 — intervention group
Group type: EXPERIMENTAL
Intervention: Ang II infusion
Number of subjects: 17
Study 7831698 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrorphan (loading dose 60 to 150 mg, maintenance infusion maximum total dose 3310 mg)
Number of subjects: 66
Study 7831698 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrorphan (loading dose 145 to 260 mg, maintenance infusion 30 to 70 mg/h)
Number of subjects: 66
Study 7831698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 2194442 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids (high dose, short term)
Number of subjects: 0
Study 2194442 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 0
Study 508554 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 12
Study 508554 — intervention group
Group type: EXPERIMENTAL
Intervention: Dothiepin
Number of subjects: 12
Study 508554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30010027 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART Camp intervention
Number of subjects: 204
Study 30010027 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 204
Study 26655433 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week home-based telerehabilitation exercise program using virtual reality (VR) in addition to usual care
Number of subjects: 0
Study 26655433 — intervention group
Group type: COMPARATOR
Intervention: 4-week written home exercise program (usual care discharge home program)
Number of subjects: 0
Study 25072647 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dorzolamide 2% and timolol 0.5% twice daily postoperatively until gas dissolution
Number of subjects: 21
Study 25072647 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control group)
Number of subjects: 21
Study 22947356 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg to 20 mg daily
Number of subjects: 185
Study 22947356 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg to 40 mg daily
Number of subjects: 185
Study 22947356 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg to 20 mg + Lisinopril 10 mg to 40 mg
Number of subjects: 185
Study 22947356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 20453055 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation
Number of subjects: 1474
Study 20453055 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral skills
Number of subjects: 1474
Study 20453055 — intervention group
Group type: EXPERIMENTAL
Intervention: Information
Number of subjects: 1474
Study 17565094 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive-writing
Number of subjects: 40
Study 17565094 — intervention group
Group type: EXPERIMENTAL
Intervention: History-writing
Number of subjects: 40
Study 17565094 — intervention group
Group type: COMPARATOR
Intervention: Time-management
Number of subjects: 40
Study 16130176 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of nemifitide administered by standard needle/syringe
Number of subjects: 12
Study 16130176 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of nemifitide administered by needle-free injection
Number of subjects: 12
Study 16130176 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of nemifitide administered by needle-free injection
Number of subjects: 12
Study 12135935 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin or Cerivastatin
Number of subjects: 80
Study 12135935 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (Control)
Number of subjects: 80
Study 10680452 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplemented TPN for 10 days
Number of subjects: 11
Study 10680452 — intervention group
Group type: COMPARATOR
Intervention: Conventional TPN for 8-63 days
Number of subjects: 11
Study 7566519 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine
Number of subjects: 0
Study 7566519 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0
Study 1837469 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge Whitacre needle
Number of subjects: 200
Study 1837469 — intervention group
Group type: COMPARATOR
Intervention: 22-gauge Whitacre needle
Number of subjects: 200
Study 1837469 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (22-gauge and 25-gauge)
Number of subjects: 200
Study 7072313 — intervention group
Group type: EXPERIMENTAL
Intervention: acebutolol (400 mg/die)
Number of subjects: 42
Study 7072313 — intervention group
Group type: EXPERIMENTAL
Intervention: diuretic mefrusid (25 mg/die)
Number of subjects: 42
Study 7072313 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of acebutolol and mefrusid
Number of subjects: 42
Study 31778707 — intervention group
Group type: COMPARATOR
Intervention: High altitude (HA)
Number of subjects: 8
Study 30567753 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (560 or 840 mg daily) combined with high-dose methotrexate (HD-MTX) at 3.5 g/m2 every 2 weeks for a total of 8 doses (4 cycles) and rituximab.
Number of subjects: 15
Study 30567753 — intervention group
Group type: COMPARATOR
Intervention: High-dose methotrexate (HD-MTX)
Number of subjects: 15
Study 27155289 — intervention group
Group type: EXPERIMENTAL
Intervention: Labels containing 'tsp' or 'teaspoon' units (alone or with 'mL')
Number of subjects: 2110
Study 27155289 — intervention group
Group type: COMPARATOR
Intervention: Labels containing 'mL' only
Number of subjects: 2110
Study 27155289 — intervention group
Group type: EXPERIMENTAL
Intervention: Labels with 'teaspoon' spelled out
Number of subjects: 2110
Study 27155289 — intervention group
Group type: EXPERIMENTAL
Intervention: Labels with 'teaspoon' and 'mL'
Number of subjects: 2110
Study 27155289 — intervention group
Group type: EXPERIMENTAL
Intervention: Labels with 'tsp' and 'mL'
Number of subjects: 2110
Study 25155032 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological prophylaxis training
Number of subjects: 48
Study 25155032 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 22747705 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing with computer assistance (MICA)
Number of subjects: 400
Study 22747705 — intervention group
Group type: COMPARATOR
Intervention: Educational videos on contraception, STIs, and pre‐conception counseling
Number of subjects: 400